JP7027437B2 - ＲＯＲ－γモジュレーター - Google Patents

ＲＯＲ－γモジュレーター Download PDF

Info

Publication number
JP7027437B2
JP7027437B2 JP2019544789A JP2019544789A JP7027437B2 JP 7027437 B2 JP7027437 B2 JP 7027437B2 JP 2019544789 A JP2019544789 A JP 2019544789A JP 2019544789 A JP2019544789 A JP 2019544789A JP 7027437 B2 JP7027437 B2 JP 7027437B2
Authority
JP
Japan
Prior art keywords
formula
compounds
alkyl
compound
och
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019544789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535813A5 (enExample
JP2019535813A (ja
Inventor
ナス，ジョン
ハリス，ジェイソン
モハン，ラジュ
Original Assignee
エスカリア バイオサイエンシーズ，ビーブイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスカリア バイオサイエンシーズ，ビーブイ filed Critical エスカリア バイオサイエンシーズ，ビーブイ
Publication of JP2019535813A publication Critical patent/JP2019535813A/ja
Publication of JP2019535813A5 publication Critical patent/JP2019535813A5/ja
Application granted granted Critical
Publication of JP7027437B2 publication Critical patent/JP7027437B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Processing Of Color Television Signals (AREA)
  • Picture Signal Circuits (AREA)
  • Details Of Television Scanning (AREA)
JP2019544789A 2016-10-27 2017-10-27 ＲＯＲ－γモジュレーター Expired - Fee Related JP7027437B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662413907P 2016-10-27 2016-10-27
US62/413,907 2016-10-27
PCT/US2017/058755 WO2018081558A1 (en) 2016-10-27 2017-10-27 Ror-gamma modulators

Publications (3)

Publication Number Publication Date
JP2019535813A JP2019535813A (ja) 2019-12-12
JP2019535813A5 JP2019535813A5 (enExample) 2020-12-03
JP7027437B2 true JP7027437B2 (ja) 2022-03-01

Family

ID=62024021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019544789A Expired - Fee Related JP7027437B2 (ja) 2016-10-27 2017-10-27 ＲＯＲ－γモジュレーター

Country Status (14)

Country Link
US (5) US10905687B2 (enExample)
EP (1) EP3532062B1 (enExample)
JP (1) JP7027437B2 (enExample)
KR (1) KR102598775B1 (enExample)
CN (1) CN110139652B (enExample)
AU (1) AU2017348345B2 (enExample)
BR (1) BR112019008548A2 (enExample)
CA (1) CA3042080A1 (enExample)
ES (1) ES2928904T3 (enExample)
IL (1) IL266261B (enExample)
MX (1) MX392163B (enExample)
PH (1) PH12019500949A1 (enExample)
RU (1) RU2753490C2 (enExample)
WO (1) WO2018081558A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928904T3 (es) 2016-10-27 2022-11-23 Escalier Biosciences Bv Moduladores de ROR-gamma
JP2021517563A (ja) 2018-03-12 2021-07-26 エスカリア バイオサイエンシーズ，ビーブイ 二環式ＲＯＲγモジュレーター
BR112020018718A2 (pt) 2018-03-12 2021-03-09 Escalier Biosciences B.V. Moduladores de ror-gama espirocíclicos
CA3159637A1 (en) * 2019-11-05 2021-05-14 Dermira, Inc. Ror gamma t inhibitors and topical uses thereof
CA3186628A1 (en) * 2020-06-30 2022-01-06 Dermira, Inc. Ror.gamma.t inhibitors and topical uses thereof
CN111892599B (zh) * 2020-08-14 2023-01-13 黄芳 一种2,5-二氮杂双环[2.2.2]辛烷-2-羧酸叔丁酯的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520837A (ja) 2008-05-15 2011-07-21 ナームローゼ・フエンノートチヤツプ・オルガノン Ｎ−（１，１，１，３，３，３−ヘキサフルオロ−２−ヒドロキシプロパン−２−イル）ベンジル−ｎ’−アリールカルボニルピペラジン誘導体
US20140187554A1 (en) 2011-05-16 2014-07-03 The Scripps Research Institute Modulators of the nuclear hormone receptor ror
JP2015522057A (ja) 2012-07-11 2015-08-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのアリールスルタム誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432957B1 (en) * 2001-06-29 2002-08-13 Kowa Co., Ltd. Piperazine derivative
WO2004032933A1 (ja) * 2002-10-11 2004-04-22 Kowa Co., Ltd. 癌の処置方法
HUP1100166A2 (en) * 2011-03-29 2012-12-28 Sanofi Sa Reductive amination process for preparation of dronedarone using amine intermediary compound
PL2758060T3 (pl) * 2011-09-19 2018-04-30 ETH Zürich Modulatory ROR-gamma do leczenia powikłań cukrzycy typu II
JP2018513123A (ja) * 2015-03-12 2018-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法
ES2928904T3 (es) 2016-10-27 2022-11-23 Escalier Biosciences Bv Moduladores de ROR-gamma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520837A (ja) 2008-05-15 2011-07-21 ナームローゼ・フエンノートチヤツプ・オルガノン Ｎ−（１，１，１，３，３，３−ヘキサフルオロ−２−ヒドロキシプロパン−２−イル）ベンジル−ｎ’−アリールカルボニルピペラジン誘導体
US20140187554A1 (en) 2011-05-16 2014-07-03 The Scripps Research Institute Modulators of the nuclear hormone receptor ror
JP2015522057A (ja) 2012-07-11 2015-08-03 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのアリールスルタム誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Xue, Xiao-xian; Zhang, Yan; Xu, Yong; Song, Hong-rui，Synthesis and preliminary bioactivities evaluation of retinoic acid-related orphan receptor γ inhibitors，Zhongguo Yaowu Huaxue Zazhi ，2014年，24(4),，279-285

Also Published As

Publication number Publication date
BR112019008548A2 (pt) 2019-09-17
EP3532062A1 (en) 2019-09-04
ES2928904T3 (es) 2022-11-23
RU2753490C2 (ru) 2021-08-17
CN110139652B (zh) 2022-10-11
US20230277527A1 (en) 2023-09-07
AU2017348345A1 (en) 2019-05-30
MX2019004973A (es) 2019-09-19
IL266261A (en) 2019-06-30
CA3042080A1 (en) 2018-05-03
US20210069182A1 (en) 2021-03-11
EP3532062B1 (en) 2022-07-20
RU2019115059A (ru) 2020-11-27
PH12019500949A1 (en) 2019-08-05
US10905687B2 (en) 2021-02-02
EP3532062A4 (en) 2020-04-15
RU2019115059A3 (enExample) 2020-12-18
CN110139652A (zh) 2019-08-16
KR102598775B1 (ko) 2023-11-03
MX392163B (es) 2025-03-21
JP2019535813A (ja) 2019-12-12
US20190269674A1 (en) 2019-09-05
US20240216361A1 (en) 2024-07-04
KR20190096979A (ko) 2019-08-20
US20220175765A1 (en) 2022-06-09
WO2018081558A1 (en) 2018-05-03
AU2017348345B2 (en) 2022-01-27
IL266261B (en) 2022-07-01

Similar Documents

Publication Publication Date Title
JP7027437B2 (ja) ＲＯＲ－γモジュレーター
AU2014236719B2 (en) Compounds and methods for inducing chondrogenesis
US11827605B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
US8722672B2 (en) Topical pharmaceutical composition including rel-N-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4′-(trifluoromethoxY)-[1,1′-biphenyl]-3-carboxamide
JP2021534215A (ja) 病的症状の治療における使用のための芳香族分子
US20170266157A1 (en) Methods for wound healing and scar prevention
CN105683176A (zh) 肝脏x受体(lxr)调节剂
JP2025111455A (ja) 抗増殖活性を有するフェノキシ（ヘテロ）アリールエーテル
AU2007238816B2 (en) Methods for modulating formation and progression of cellulite
RS57133B1 (sr) Kompozicija za tretman poremećaja hipoaktivno umanjenje seksualne želje
HK40012522B (en) Ror-gamma modulators
HK40012522A (en) Ror-gamma modulators
RU2661007C2 (ru) Фармацевтическая композиция ингибитора папилломавируса
ES3022196A1 (es) Derivados de 2-indolinona y usos de los mismos
CN109776373A (zh) 酰胺取代的吡咯烷酰胺衍生物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201023

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220216

R150 Certificate of patent or registration of utility model

Ref document number: 7027437

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees